This content is machine translated Heavily pretreated multiple myeloma New therapeutic option: an antibody that targets CD38 Results from an ongoing phase II trial of the monoclonal antibody daratumumab were presented at the ASCO Congress. This targets the protein CD38, which is highly expressed on myeloma cells.…
